FUKOKU MUTUAL LIFE INSURANCE Co Has $782,000 Stock Position in Danaher Co. (NYSE:DHR)

FUKOKU MUTUAL LIFE INSURANCE Co decreased its stake in Danaher Co. (NYSE:DHR) by 10.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,813 shares of the conglomerate’s stock after selling 313 shares during the quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Danaher were worth $782,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the 2nd quarter valued at about $25,000. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Danaher during the second quarter worth $51,000. Financial Connections Group Inc. acquired a new position in Danaher during the second quarter valued at approximately $51,000. Finally, Western Pacific Wealth Management LP bought a new position in Danaher in the 1st quarter valued at approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 18.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.9 %

Danaher stock opened at $239.45 on Friday. The stock has a market capitalization of $172.95 billion, a price-to-earnings ratio of 45.70, a PEG ratio of 4.44 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a twelve month low of $204.15 and a twelve month high of $281.70. The stock has a 50 day moving average of $263.42 and a two-hundred day moving average of $260.64.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 EPS. The company’s revenue was up 3.1% on a year-over-year basis. As a group, research analysts expect that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Raymond James dropped their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Wells Fargo & Company initiated coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. StockNews.com upgraded Danaher from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Barclays decreased their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Finally, Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.